- Developing innovative cancer immunotherapies
- Four lead products in development
- Phase II and phase I/II studies in progress or preparation targeting multiple cancer indications
What the company does
AIM-listed Scancell Holdings PLC (LON:SCLP) is at the vanguard of advances in the emerging field of immuno-oncology and is working on two technologies that are showing promise – they are the ImmunoBody and Moditope platforms.
The former has spawned the company’s most advanced cancer drugs, SCIB-1 and SCIB-2. It is also developing MODI-1 and MODI-2 from the Moditope platform.
The study will initially assess the safety and efficacy of the treatment in 25 people with a metastatic form of skin cancer, melanoma. SCIB-1 will be used in harness with Merck’s checkpoint inhibitor Keytruda.
Scancell remains in discussions with regulators over the minutiae of a parallel clinical assessment in the US.
A £3.9mln injection from the life sciences fund Vulpes will effectively bankroll the latest R&D.
The deficit for the year was £5.6mln as development expenditure grew to £4.15mln.
In September, Scancell signed its first collaboration deal with an unnamed “leading antibody technology company” as it bids to develop an early-stage technology created to directly kill tumour cells.
The company expects to generate meaningful clinical data in the next two years from all four of its drug candidates (see below).
In recent updates investors have been told CRUK is planning a clinical trial to investigate the safety and efficacy of the SCIB2-nanoparticle complex in patients with solid tumours.
And a planned phase I/II clinical study is of MODI-1 is expected to begin in the second half.